secwatch.observer — SEC 8-K summary
======================================

Issuer:     WINDTREE THERAPEUTICS INC /DE/ (WINT)
CIK:        0000946486
Form:       8-K
Filed at:   2024-09-25T23:59:59+00:00
Accession:  0001437749-24-029936
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Windtree announces positive Phase 2b topline results for istaroxime in early cardiogenic shock
--------------------------------------------------------------------------------

- Istaroxime met primary endpoint: significantly improved systolic blood pressure profile over six hours vs placebo.
- Significant improvements in many secondary endpoints; safety profile favorable, consistent with prior trials.
- Study tested two dosing regimens (decreasing and constant) over up to 60 hours infusion to optimize late-stage design.
- Detailed results to be presented at Heart Failure Society of America on Sept 30, 2024; investor call planned.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/946486/000143774924029936/0001437749-24-029936-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/946486/000143774924029936/wint20240924c_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-029936

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer